Gene therapy for lipoprotein lipase deficiency
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: The present review summarizes the clinical development of adeno-associated viral vector (AAV)1-lipoprotein lipase (LPL)S447X gene therapy (alipogene tiparvovec) for lipoprotein lipase deficiency. Lipoprotein lipase deficiency is a rare inherited disease characterized by severe hypertriglyceridaemia, chylomicronaemia and risk of recurrent pancreatitis or other complications. AAV1-LPLS447X gene therapy is based on the rationale that by adding episomal copies of functional LPL genes into muscle cells lacking active LPL, metabolic function could be improved or restored. RECENT FINDINGS: AAV1-LPLS447X is a nonreplicating and nonintegrating AAV of serotype 1 designed to deliver and express the human LPL gene variant S447X. The clinical development programme for AAV1-LPLS447X consisted of two observational studies, three open-label interventional studies and one case note review analysis. Intramuscular administration of AAV1-LPLS447X was generally well tolerated and was associated with reduction in overall pancreatitis incidence and signs of clinical improvement up to 2 years after administration. Results of interventional studies suggest that markers of postprandial metabolism could be more accurate than fasting plasma triglyceride concentration to monitor the effect of AAV1-LPLS447X . SUMMARY: The overall benefit-risk ratio of AAV1-LPLS447X gene therapy appears positive to date, particularly for the patients presenting the highest risk of complications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical trials, intramuscular injection of alipogene tiparvovec was associated with reduction in the incidence of pancreatitis and was well tolerated”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [172]
In the citing paper
“Unfortunately, TG drifted back to baseline levels within 6 months, although a few exceptional cases experienced sustained benefits.84–87”
From Clinical review on triglycerides (2020) · cites this paper as [87]
Citations
Cites
T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., et al. (1995) · Science · doi:10.1126/science.270.5235.475 · Cited by 1,550
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Self-citationState-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia
Grossman, M., Raper, S. E., Kozarsky, K., Stein, E. A., Engelhardt, J. F., Muller, D., Lupien, P. J., & Wilson, J. M. (1994) · Nature Genetics · doi:10.1038/ng0494-335 · Cited by 559
Gene therapy: trials and tribulations
Somia, N., & Verma, I. M. (2000) · Nature Reviews Genetics · doi:10.1038/35038533 · Cited by 554
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Self-citation
Research works printed but not linked: 1
- Mingozzi, 2011, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12:341-355., Erratum in: Nat Rev Genet, 12, 515
Cited by
Items 101–181 of 181
Gene therapy in neuronopathic lysosomal storage disorders
Donald, A., Horgan, C., López, M. J. D. C., Jones, S., & Wynn, R. F. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.05.010 · Cited by 7
Khalifeh, M., Santos, R. D., Oskuee, R. K., Badiee, A., Aghaee‐Bakhtiari, S. H., & Sahebkar, A. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101197 · Cited by 7
Tsaregorodtseva, T. S., Radyukhina, M. A., Ayupova, A. I., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114818 · Cited by 5
“It required multiple injections with a total dose of up to 3 × 10 12 vp into the muscles of the lower extremities [30].”
Balasubramanian, S., Aggarwal, P., & Sharma, S. (2021) · StatPearls · Cited by 9
Weijs, B. M., Oostveen, R. F., Kraaijenhof, J. M., & Stroes, E. S. G. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000906 · Cited by 5
“Over the last decades, several highly specific agents have been developed to lower plasma triglyceride world’s first adeno-associated viral vector-based therapy, designed to deliver functional LPL genes to muscle cells, allowing them to produce functional LPL enzymes [39].”
Zou, Z., Mao, L., Chen, J., Wang, L., & Cai, W. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.09.006 · Cited by 5
RetractedAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch37 · Cited by 5
New Innovations: Therapies for Genetic Conditions
Rajabi, F., & Picker, J. D. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0043-9 · Cited by 5
Chreitah, A., Hijazia, K., Doya, L. J., & Salloum, A. (2021) · Oxford Medical Case Reports · doi:10.1093/omcr/omab036 · Cited by 4
“LPL gene therapy (Alipogene Tiparvovec) might be potential treatment in patients with LPL deficiency [10].”
BackgroundInborn Errors of Lipoprotein Metabolism Presenting in Childhood
Ramaswami, U., & Humphries, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-662-63123-2_36 · Cited by 4
Adachi, K., Tomono, T., Okada, H., Shiozawa, Y., Yamamoto, M., Miyagawa, Y., & Okada, T. (2021) · Gene Therapy · doi:10.1038/s41434-021-00299-x · Cited by 4
Lipoprotein Lipase Deficiency: Diet is the Key!
Patil, K., & Gupta, N. (2021) · The Indian Journal of Pediatrics · doi:10.1007/s12098-020-03640-1 · Cited by 4
“An adeno-associated viral vector (AAV)1-LPL gene therapy, alipogene tiparvovec, that introduced functional copies of the LPL into the muscle tissue of patients was initiated in a few countries but later on withdrawn due to uncertainties about reimbursement and poor demand [5].”
BackgroundIn vitro and In vivo Model Systems for Hemophilia A Gene Therapy
Mao, J., Xi, X., Kapranov, P., Dong, B., Firrman, J., Xu, R., & Xiao, W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-014 · Cited by 3
“Recent successes in gene therapy of hemophilia B, Leber congenital amaurosis (LCA), lipoprotein lipase deficiency and severe combined immunodeficiency suggest that hemophilia A gene therapy may be achieved as well [8-13].”
BackgroundBlits, B., Kirik, D., Petry, H., & Hermening, S. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_3 · Cited by 3
Huang, X., Wang, X., Feng, L., Zhou, R., Chen, W., Jiang, X., Lv, F., Xu, W., Xu, X., Xie, X., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123742 · Cited by 3
Channeling postmarketing patient data into pharmaceutical regulatory systems
Barbosa, M. D. F. S., & Smith, D. D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.07.011 · Cited by 3
Larouche, M., Brisson, D., Roy, N., Grenon, C., Poirier, P., Muhsin, M., & Gaudet, D. (2025) · JIMD Reports · doi:10.1002/jmd2.70052 · Cited by 2
“This patient was treated with Glybera 1 year before her first pregnancy which went well, without any abdominal pain or AP episode, and led to a normal delivery of a healthy baby [44].”
Self-citationThomsen, M. J., Varbo, A., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2014) · Acta bioquímica clínica latinoamericana/Acta bioquímica clínica latinoamericana · Cited by 2
Faleti, J. O., Olasore, H. S. A., Olawale, M. O., Murtala, A. A., Banjo, T. A., & Igwo-Ezikpe, M. N. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11039-w · Cited by 2
“A large number of mutations have been identified in the LPL gene (Gaudet et al. 2012).”
Fricke, U., & Schwabe, U. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_2 · Cited by 2
Moreno-Gutiérrez, D. S., Zepeda–Cervantes, J., Vaca, L. A., & Hernández-García, A. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112348 · Cited by 3
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Self-citationPRODUÇÃO E APLICAÇÃO DE SOFOROLIPÍDIOS EM COSMÉTICOS
Filipe, G. A., Lonni, A. A. S. G., & Celligoi, M. A. P. C. (2021) · doi:10.22533/at.ed.54721010414 · Cited by 2
Soyaltın, U. E., BOZKURT, A. B. K., Solmaz, A. E., Hakverdi, G., & Şimşir, İ. Y. (2022) · Ege Tıp Dergisi · doi:10.19161/etd.1209062 · Cited by 1
Clinical Management of Dyslipidemia in Infants and Toddlers
Kelley, J. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01305-y · Cited by 1
“Research using gene therapy are ongoing, however the first and only gene therapy, alipogene tiparvovec, was approved in the Euro - pean Union but was withdrawn due to excessive cost and limited efficacy [ 90, 91 ].”
van Heyningen, C., Cozma, I., & Arasaradnam, M. (2013) · International Journal of Case Reports in Medicine · doi:10.5171/2013.810803 · Cited by 1
“An assessment of the use of gene therapy for LPL and apoA5 deficiency in pregnancy is awaited (Goldberg and Hegele, 2012 ).”
BackgroundViral Vectors for Gene Therapy of Genetic Diseases: Challenges and Prospects
Nasimuzzaman, M. (2014) · Journal of Human Virology & Retrovirology · doi:10.15406/jhvrv.2015.02.00048 · Cited by 1
“AAV vectors have been used in over 117 clinical trials worldwide and promising results have been obtained from Phase 1 and Phase 2 trials for a number of diseases, including Leber’s Congenital Amaurosis [3],hemophilia[4], lipoprotein lipase deficiency [5], and congestive heart failure [6].”
MethodLipaemia in lipoprotein lipase deficiency
Liu, A., Shrestha, S., & Nanan, R. K. H. (2016) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12956 · Cited by 1
Chaves, J. D. O., de Oliveira, K. M., Figueiredo, L. S., Aguiar, G. D. S., Freitas, I. N., de Oliveira, C. D. A. R., Rios, V. K., Ribeiro, R. A., & Blanc, H. N. H. (2021) · doi:10.22533/at.ed.5472101043 · Cited by 2
Stimulation of AAV Gene Editing via DSB Repair
Mitchell, A. M., Moser, R. J., Samulski, R. J., & Hirsch, M. L. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-3509-3_8 · Cited by 1
Inborn Errors of Lipoprotein Metabolism Presenting in Childhood
Ramaswami, U., & Humphries, S. E. (2016) · Springer eBooks · doi:10.1007/978-3-662-49771-5_31 · Cited by 1
Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders
Lee, J.-H., & Hegele, R. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1311784 · Cited by 1
“The treatment is well tolerated, and within 12 weeks of administration, plasma triglycerides in patients who received alipogene tiparvovec were normalized [86,87].”
BackgroundHypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Defining public attitudes and understanding of human gene therapy in Australia
Watson, M. (2021) · ANU Open Research (Australian National University) · doi:10.25911/hpsw-sj81 · Cited by 3
The molecular basis of severe hypertriglyceridemia: from genetic counseling to gene therapy.
Gavish, D. (2013) · PubMed · Cited by 1
Prenatal Diagnosis of Disorders of Lipid Metabolism
Humphries, S. E., Mole, S., & WINCHESTER, B. G. (2015) · Wiley eBooks · doi:10.1002/9781118981559.ch20
Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies
Moens, S. J. B., Hassing, C., Nieuwdorp, M., Stroes, E. S. G., & Dallinga‐Thie, G. M. (2013) · Clinical Lipidology · doi:10.2217/clp.13.23
Lipids: new biology and therapeutic targets revealed through human genetics
Runz, H. (2013) · Clinical Lipidology · doi:10.2217/clp.13.22
Alipogene Tiparvovec: Gene Therapy for Familial Lipoprotein Lipase Deficiency
Miller, N. (2015) · CRC Press eBooks · doi:10.1201/b18002-45
Mitchell, A. M. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/f5kg-n202
Chemical Modulation of AAV Trafficking
Berry, G. E. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dpe3-gy73
Produção e purificação de vetores virais adeno-associados para terapia génica
Abrunheiro, V. A. J. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Curado, T. F. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-13062017-162234
Foamy virus vector integration and application in gene therapy
Sweeney, N. P. (2015) · Spiral (Imperial College London) · doi:10.25560/50704
Lipoprotein Lipase and Its Interactions With Phospholipids
Wang, Y., & Sun‐Waterhouse, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-100596-5.21479-0
VIII. Development of New Strategy and Modality of Lipid Management
Okazaki, H. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.735
Nicolson, S. C. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gbv4-z740
DETERMINANTS OF AAV TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER
Albright, B. H. (2018) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vnpr-wx33
IMOBILIZAÇÃO DE LEVEDURAS EM GEL DE ALGINATO E PECTINA
Gonçalves, L. D. F., & Rodrigues, S. Á. (2021) · doi:10.22533/at.ed.54721010411
MONITORAMENTO MICROCONTROLADO DO CULTIVO MIXOTRÓFICO DE HAEMATOCOCCUS PLUVIALIS
Pinto, L., & Anschau, A. (2021) · doi:10.22533/at.ed.54721010418
ATIVIDADES BIOLÓGICAS DE PSEUDOBOMBAX MARGINATUM (A.ST.-HIL., JUSS. & CAMBESS.) A. ROBYNS
dos Santos, N. A. M., da Silva, J. F., de Souza, T. P., & Ramalho, H. M. M. (2021) · doi:10.22533/at.ed.5472101048 · Cited by 1
A RELEVÂNCIA E OS MECANISMOS DE AÇÃO DA TOXINA BOTULÍNICA COMO TERAPÊUTICA ESTÉTICA
de Aguiar, L. M. N. M., da Silva, L. D. F. L., da Silva, S. S., dos Santos, G. M., da Silva, D. M., de Carvalho, A. M., de Matos, R. R. C., Monteiro, J. F. B., & de Aguiar, J. D. J. C. (2021) · doi:10.22533/at.ed.54721010415
Rodrigues, D. C., Walcher, D. L., da Cunha, C. N. D. O., Mattos, G. T., de Souza, N. F. G. C., de Ávila, L. F. D. C., Ramos, D. F., & Scaini, C. J. (2021) · doi:10.22533/at.ed.5472101042
EXPRESSÃO DA PROTEÍNA HIF-1α EM CARCINOMA DE CÉLULAS ESCAMOSAS DA CAVIDADE ORAL
Vimercati, B. D. S., Evaristo, S. D. O., Queiroz, M. E. S., de Oliveira, M. M., de Assis, A. L. E. M., Borçoi, A. R., de Souza, R. P., Archanjo, A. B., & da Silva, A. M. Á. (2021) · doi:10.22533/at.ed.5472101049
Francischini, I. A. G., & da Silva, C. H. T. D. P. (2021) · doi:10.22533/at.ed.54721010410
AVALIAÇÃO DE AMILASES POR FERMENTAÇÃO SUBMERSA DO FUNGO ASPERGILLUS ACULEATUS
de Vasconcelos, A. F., Chamy, M. N. C. L., Costa, A. B., Costa, B. K. B. D. S., Lima, U. D. O., Prá, A. C. D., Reis, R. D. S., & de Brito, R. G. (2021) · doi:10.22533/at.ed.5472101041
COMPOSIÇÃO QUÍMICA E ATIVIDADE ANTIBACTERIANA DO ÓLEO ESSENCIAL DE VITEX AGNUS-CASTUS L. (LAMIACEAE)
Gonçalves, R., Ayres, V. F. D. S., de Carvalho, C. E., de Souza, M. G. M., Guimarães, A. C., Corrêa, G. M., Martins, C. H. G., Takeara, R., Silva, E. D. O., & Crotti, A. E. M. (2021) · doi:10.22533/at.ed.5472101044
Leal, C. D. F., Ribeiro, L. R., & de Almeida, D. M. (2021) · doi:10.22533/at.ed.5472101047
ISOLAMENTO E IDENTIFICAÇÃO BIOQUÍMICA DE Salmonella spp. NA CADEIA PRODUTIVA DE FRANGOS
da Silva, S. E. L., Miranda, V. S., Ferreira, N. L., Tomaz, L. D., da Silva, V. S., & Silva, K. S. (2021) · doi:10.22533/at.ed.5472101045
UTILIZAÇÃO DE VETORES VIRAIS NA TERAPIA GÊNICA
Barroso, E. P., Félix, S. S. L., Félix, A. J. L., Félix, M. J. E. L., Sinhorin, G. H., Júnior, Y. F. D. M., da Silva, A. G., Ferreira, J. P., de Arruda, É. F., & Filho, A. N. D. S. G. (2021) · doi:10.22533/at.ed.54721010416
EXPANSION OF SCHISTOSOMIASIS IN A LOCALITY IN SÃO LUÍS, MARANHÃO, BRAZIL
Nogueira, A. D. J. L., Mendes, R. J. D. A., Filho, A. A. P., Aguiar, L. S., Nogueira, I. B. D. C., Fabri, A. N., Ambrósio, H. T. M. D. J., Araújo, K. R. F., & Rosa, I. G. (2021) · doi:10.22533/at.ed.54721010417
CONTRACEPTIVOS ORAIS COMBINADOS E A BIOLOGIA DA INSULINA
Chaves, J. D. O., de Oliveira, C. D. A. R., Blanc, H. N. H., & Ribeiro, R. A. (2021) · doi:10.22533/at.ed.54721010412
Akkaliyev, M., Aukenov, N., Massabayeva, M., Apsalikov, B., Rakhyzhanova, S., & Kuderbaev, M. (2021) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/jcmk/11223
“This pathology is characterized by severe hypertriglyceridemia and the risk of recurrent pancreatitis or other complications [64].”
BackgroundPrenatal Diagnosis of Disorders of Lipid Metabolism
Davison, J. E., Humphries, S. E., WINCHESTER, B. G., & Mole, S. (2021) · Wiley eBooks · doi:10.1002/9781119676980.ch25
Mattia, R. A. D. (2022) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/132617
Lipaemia in lipoprotein lipase deficiency
(2016) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12956_2
Popovich, P. G. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733447321.793557618
Monogene Fettstoffwechselstörungen
Merkel, M., & März, W. (2014) · Springer eBooks · doi:10.1007/978-3-642-45188-1_43
Tirthal, U. A. (2022) · Journal of Pharmaceutical Negative Results · doi:10.47750/pnr.2022.13.s08.489
“They have been licensed in Europe for the treatment of lipoprotein lipase deficiency and have been successfully utilised in clinical trials to treat genetic disorders such as haemophilia B2[9].”
MethodKwiatek, M., Michalski, A., Abramowicz, K., Rutyna, P., Wasiak, M., Reichert, M., & Lisowski, L. (2023) · Lekarz Wojskowy · doi:10.53301/lw/156374
“Those include Glybera (AAV1) for treatment of inherited metabolic disorder lipoprotein lipase deficiency (LPLD), unfortunately withdrawn from the market in 2017 [8], Luxturna (AAV2) for treatment of an inherited retinal diseases (IRDs) [9] and, most recently, Zolgensma (AAV9) for treatment of spinal muscular atrophy t…”
Definitive Treatments for Chronic Granulomatous Disease with a Focus on Gene Therapy
Santilli, G., & Thrasher, A. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-23752-2_33
Role of lipoprotein lipase variants in metabolic disorders and cardiovascular diseases
Rafaqat, S., Rafaqat, S., Sharif, S., & Klisic, A. N. (2024) · Arhiv za farmaciju · doi:10.5937/arhfarm74-48070
“Gaudet et al. (23) further highlighted that LPL deficiency is a rare inherited disease associated with severe hypertriglyceridemia, chylomicronemia, and the increased risk of recurrent pancreatitis, among other potential complications.”
BackgroundIitake, C., Masuda, D., Koseki, M., & Yamashita, S. (2020) · Figshare · doi:10.6084/m9.figshare.13297272
Terapia génica: sistemas de entrega, mecanismos moleculares e abordagens terapêuticas aprovadas
Biscaia, C. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Bilek, I. I., Zulfiharov, A. O., & Vlasenko, N. E. (2024) · Electronic Sumy State University Institutional Repository (Sumy State University)
Régulation épigénétique de la lipolyse intravasculaire des triglycérides
Pinkele, C. (2015) · theses.fr (ABES) · doi:10.70675/c1f85e63z2bd1z45a6z89bbzc71288b94dd3 · Cited by 1
Gene therapy approach on Charcot-Marie-Tooth type 1A rats
Hajjar, H. (2018) · theses.fr (ABES) · doi:10.70675/014f2329za7dbz40a5z9c75z92e60af2b4a0 · Cited by 1
Celiński, R., Kocki, J., Grzywa-Celińska, A., Szewczyk, K. D. S., & Berecka-Rycerz, A. (2026) · Applied Sciences · doi:10.3390/app16104806
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Self-citation
Metadata
- Authors
- Gaudet, D., Méthot, J., & Kastelein, J.
- Affiliations
- Hôpital de Chicoutimi (CA)
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Gaudet, Daniel
- Venue
- Current Opinion in Lipidology
- Published
- 2012-08
- Volume
- 23
- Issue
- 4
- Pages
- 310-320
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2019818397
- Cited by
- 178
- References
- 40
- Citations by year
- 2026: 2 · 2025: 14 · 2024: 4 · 2023: 6 · 2022: 11 · 2021: 32 · 2020: 5 · 2019: 12 · 2018: 11 · 2017: 14 · 2016: 18 · 2015: 19 · 2014: 15 · 2013: 14 · 2012: 1
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (CTP82941)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- lipoprotein lipase deficiency, gene therapy, hypertriglyceridemia, pancreatitis, intramuscular gene delivery, clinical trial results
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Humans, Lipoprotein Lipase, Safety, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.